Perspectives on prostate cancer diagnosis and treatment: a roundtable.
This roundtable was held September 30, 2000. It addressed, first of all, the accuracy and proper interpretation of the available prostate-specific antigen assays. Dr. Brawer presented data to demonstrate the specificity of the complexed prostate-specific antigen assay. Dr. Stamey counterpoised evidence that pretreatment prostate-specific antigen levels less than 9 ng/mL are attributable to benign prostatic hyperplasia and therefore are of little value as an indicator of when to initiate treatment for prostate cancer. The other roundtable participants offered reviews and new data regarding hormonal therapy as primary or adjunctive treatment of prostate cancer. Dr. Fowler presented a large retrospective series of men with locally advanced prostate cancer for whom androgen ablation was the primary therapy. Dr. Droller discussed his center's experience in integrating hormonal therapy with brachytherapy. Finally, Dr. Messing reviewed and critiqued the evidence that the combination of hormonal and radiation therapy improves survival.
Brawer
M K
MK
Northwest Prostate Institute, Seattle, Washington, USA.
Stamey
T A
TA
Fowler
J
J
Droller
M
M
Messing
E
E
Fair
W R
WR
D000368:Aged; D000728:Androgens / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D001918:Brachytherapy; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000523:psychology / Q000628:therapy; D011788:Quality of Life; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D016019:Survival Analysis; D016896:Treatment Outcome
D000728:Androgens; D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen